NewsBenzingaHC Wainwright & Co. maintient sa recommandation d’achat sur Acurx Pharmaceuticals et abaisse son objectif de cours à 11 $ HC Wainwright & Co. maintient sa recommandation d’achat sur Acurx Pharmaceuticals et abaisse son objectif de cours à 11 $ Benzinga 2026.11.12 17:21 (GMT+0) Open on Benzinga Other news HC Wainwright & Co. Maintains Buy on Acurx Pharmaceuticals, Lowers Price Target to $11 Gold Down 3%; Legence Earnings Top Views Needham Maintains Buy on Wolverine World Wide, Raises Price Target to $26 These Analysts Boost Their Forecasts On Oddity Tech After Upbeat Q3 Results Dialysis Giants DaVita and Fresenius Blocking Competition In Washington, Lawsuit Accuses B of A Securities Maintains Underperform on Teekay Tankers, Raises Price Target to $83
